| A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting (NCT03083821) | Bristol-Myers Squibb | 2017-05-16 |
| Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin (NCT03131973) | Bristol-Myers Squibb | 2017-05-13 |
| Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy (NCT03114163) | Bristol-Myers Squibb | 2017-05-12 |
| A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants (NCT03142165) | Bristol-Myers Squibb | 2017-05-11 |
| Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (NCT02971683) | Bristol-Myers Squibb | 2017-05-04 |
| First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (NCT03110107) | Bristol-Myers Squibb | 2017-05-04 |
| Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy (NCT02921126) | Bristol-Myers Squibb | 2017-04-30 |
| Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens (NCT03366610) | Bristol-Myers Squibb | 2017-04-28 |
| An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (NCT03068455) | Bristol-Myers Squibb | 2017-04-11 |
| A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan (NCT03273790) | Bristol-Myers Squibb | 2017-04-01 |
| An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (NCT03001882) | Bristol-Myers Squibb | 2017-03-29 |
| A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (NCT02927769) | Bristol-Myers Squibb | 2017-03-28 |
| A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (NCT02985957) | Bristol-Myers Squibb | 2017-03-26 |
| Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (NCT03036098) | Bristol-Myers Squibb | 2017-03-24 |
| A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (NCT02864251) | Bristol-Myers Squibb | 2017-03-17 |
| The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis (NCT03331393) | Bristol-Myers Squibb | 2017-03-16 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (NCT02998528) | Bristol-Myers Squibb | 2017-03-04 |
| A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan (NCT03165422) | Bristol-Myers Squibb | 2017-03-01 |
| Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents (NCT02928263) | Bristol-Myers Squibb | 2017-02-28 |
| Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread (NCT03165409) | Bristol-Myers Squibb | 2017-02-27 |
| A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents (NCT03670667) | Bristol-Myers Squibb | 2017-02-22 |
| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (NCT03029780) | Bristol-Myers Squibb | 2017-02-16 |
| A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (NCT02996110) | Bristol-Myers Squibb | 2017-02-02 |
| Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin (NCT03044873) | Bristol-Myers Squibb | 2017-02-02 |
| A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers (NCT03038711) | Bristol-Myers Squibb | 2017-02-01 |
| Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants (NCT03004768) | Bristol-Myers Squibb | 2017-01-26 |
| Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants (NCT03035734) | Bristol-Myers Squibb | 2017-01-25 |
| Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial (NCT03058822) | Bristol-Myers Squibb | 2017-01-25 |
| The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung (NCT03595891) | Bristol-Myers Squibb | 2017-01-20 |
| A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation (NCT02981472) | Bristol-Myers Squibb | 2017-01-19 |
| A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (NCT02982954) | Bristol-Myers Squibb | 2017-01-16 |
| Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (NCT03016325) | Bristol-Myers Squibb | 2017-01-13 |
| A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants (NCT02985632) | Bristol-Myers Squibb | 2017-01-11 |
| Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (NCT02966548) | Bristol-Myers Squibb | 2017-01-04 |
| Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma (NCT03504696) | Bristol-Myers Squibb | 2016-12-20 |
| Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC) (NCT03425825) | Bristol-Myers Squibb | 2016-12-15 |
| Long Term Quality of Life in Melanoma Patients in Netherlands (NCT03450876) | Bristol-Myers Squibb | 2016-12-15 |
| A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread (NCT03161145) | Bristol-Myers Squibb | 2016-12-09 |
| A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock. (NCT02960854) | Bristol-Myers Squibb | 2016-12-07 |
| Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (NCT02990611) | Bristol-Myers Squibb | 2016-12-06 |
| A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome (NCT02915159) | Bristol-Myers Squibb | 2016-12-06 |
| A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (NCT02913313) | Bristol-Myers Squibb | 2016-11-30 |
| Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries (NCT02581644) | Bristol-Myers Squibb | 2016-11-29 |
| Study of BMS-986012 in Subjects With Small Cell Lung Caner (NCT02949895) | Bristol-Myers Squibb | 2016-11-29 |
| A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (NCT02935634) | Bristol-Myers Squibb | 2016-11-29 |
| Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (NCT02899299) | Bristol-Myers Squibb | 2016-11-29 |
| Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries (NCT02632890) | Bristol-Myers Squibb | 2016-11-29 |
| A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US (NCT04141228) | Bristol-Myers Squibb | 2016-11-29 |
| Trial of BMS-986012 in Combination With Platinum and Etoposide (NCT02815592) | Bristol-Myers Squibb | 2016-11-28 |
| Real-World Evidence and Treatment Patterns: Head and Neck Cancer (NCT03157674) | Bristol-Myers Squibb | 2016-11-24 |
| Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy (NCT02791386) | Bristol-Myers Squibb | 2016-11-22 |
| Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis (NCT02931838) | Bristol-Myers Squibb | 2016-11-15 |
| Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02823574) | Bristol-Myers Squibb | 2016-11-08 |
| A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment (NCT02902679) | Bristol-Myers Squibb | 2016-11-01 |
| A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects (NCT02959060) | Bristol-Myers Squibb | 2016-11-01 |
| A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects (NCT02957448) | Bristol-Myers Squibb | 2016-11-01 |
| Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy (NCT02940639) | Bristol-Myers Squibb | 2016-10-27 |
| A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (NCT02905266) | Bristol-Myers Squibb | 2016-10-27 |
| Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States (NCT03199846) | Bristol-Myers Squibb | 2016-10-25 |
| A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (NCT02857426) | Bristol-Myers Squibb | 2016-10-21 |
| Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome (NCT02843659) | Bristol-Myers Squibb | 2016-10-18 |
| Phase 1 Study of Mesothelin-ADC (NCT02884726) | Bristol-Myers Squibb | 2016-10-14 |
| Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116) | Bristol-Myers Squibb | 2016-10-12 |
| Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices (NCT02856646) | Bristol-Myers Squibb | 2016-10-07 |
| A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage (NCT03189069) | Bristol-Myers Squibb | 2016-10-06 |
| An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (NCT02869789) | Bristol-Myers Squibb | 2016-10-05 |
| Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570) | Bristol-Myers Squibb | 2016-10-05 |
| Study With Healthy Japanese and Non-Asian Participants With BMS-986231 (NCT02932969) | Bristol-Myers Squibb | 2016-10-04 |
| Observational Study for Lung Cancer Patients Treated With Nivolumab (NCT03382496) | Bristol-Myers Squibb | 2016-10-01 |
| Yervoy Pregnancy Surveillance Study (NCT02854488) | Bristol-Myers Squibb | 2016-09-30 |
| Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting (NCT02037737) | Bristol-Myers Squibb | 2016-09-30 |
| Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis (NCT02864264) | Bristol-Myers Squibb | 2016-09-14 |
| A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects (NCT02922452) | Bristol-Myers Squibb | 2016-09-01 |
| Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants (NCT02912234) | Bristol-Myers Squibb | 2016-09-01 |
| A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body (NCT03241264) | Bristol-Myers Squibb | 2016-08-28 |
| A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer (NCT02828124) | Bristol-Myers Squibb | 2016-08-23 |
| Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects (NCT02705989) | Bristol-Myers Squibb | 2016-08-18 |
| An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (NCT02763761) | Bristol-Myers Squibb | 2016-08-16 |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (NCT02726581) | Bristol-Myers Squibb | 2016-08-10 |
| Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy (NCT02910999) | Bristol-Myers Squibb | 2016-08-09 |
| Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects (NCT02880670) | Bristol-Myers Squibb | 2016-08-01 |
| Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice (NCT02847728) | Bristol-Myers Squibb | 2016-07-28 |
| A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (NCT02790125) | Bristol-Myers Squibb | 2016-07-28 |
| Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (NCT02719613) | Bristol-Myers Squibb | 2016-07-15 |
| An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (NCT02743494) | Bristol-Myers Squibb | 2016-07-14 |
| A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur (NCT03769558) | Bristol-Myers Squibb | 2016-07-12 |
| Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab (NCT03200977) | Bristol-Myers Squibb | 2016-07-01 |
| A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects (NCT02807909) | Bristol-Myers Squibb | 2016-07-01 |
| ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE (NCT02836457) | Bristol-Myers Squibb | 2016-07-01 |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (NCT02754141) | Bristol-Myers Squibb | 2016-06-21 |
| An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT02737475) | Bristol-Myers Squibb | 2016-06-17 |
| A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot (NCT03521908) | Bristol-Myers Squibb | 2016-06-13 |
| Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings (NCT02758769) | Bristol-Myers Squibb | 2016-06-07 |
| Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation (NCT03087487) | Bristol-Myers Squibb | 2016-06-01 |
| A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (NCT02713867) | Bristol-Myers Squibb | 2016-05-24 |
| Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis (NCT02763969) | Bristol-Myers Squibb | 2016-05-18 |
| An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (NCT02750514) | Bristol-Myers Squibb | 2016-05-09 |
| An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (NCT02667587) | Bristol-Myers Squibb | 2016-05-09 |
| A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates (NCT02762123) | Bristol-Myers Squibb | 2016-05-01 |
| The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects (NCT02832180) | Bristol-Myers Squibb | 2016-05-01 |